CD8⁺ T cells in multiple sclerosis

Abstract

Introduction: CD8⁺ T cells were originally considered to exert a suppressive role in demyelinating disease because of bias toward the CD4⁺ T cell-mediated experimental autoimmune encephalomyelitis, the most common multiple sclerosis (MS) model. However, recent studies of human MS lesion samples and cerebrospinal fluid (CSF) provided compelling evidence about the pathogenic role of CD8⁺ T cells. In this article, we discuss the theoretical roles of different CD8⁺ T-cell subsets in MS.

Areas covered: A revised focus from CD4⁺ to CD8⁺ T cell-mediated demyelinating disease is summarized. Clonal expansion of CD8⁺ T cells in MS lesions and in vitro evidence that CD8⁺ T cells injure every central nervous system (CNS) cell type and transect axons are discussed. The role of CD8⁺ T cells in two animal models of MS and of regulatory, interleukin (IL)-17-secreting CD8⁺ T cells is reviewed. Lastly, an overview about the pathogenic and/or beneficial role of various CD8⁺ T-cell subsets is offered.

Expert opinion: Growing evidence supports the pathogenic role of CD8⁺ T cells. Clonally expanded CD8⁺ T cells within MS lesions may damage the nervous system. Revealing the specific antigen is critical to design novel efficient treatments with minimal adverse effects. Increasing evidence exists for the role of regulatory, IL-17-secreting CD8⁺ T cells in MS.

Keywords::

• animal models
• CD8⁺ T cells
• central nervous system
• clinical trial
• MHC class I
• multiple sclerosis
• regulatory T cells

Acknowledgments

The authors acknowledge, with thanks, support from the Applebaum, Hilton, Peterson and Sanford Foundations, the Minnesota Partnership Award for Biotechnology and Medical Genomics and the McNeilus family.

Notes

This box summarizes key points contained in the article.